Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG1MPD)

• Drug Name: TH-9229 Drug Info
• Synonyms: Protectazem

Indication

Disease Entry	ICD 11	Status	REF
Reperfusion injury	ND56.Z	Terminated	[1]

• Cross-matching ID:
  TTD Drug ID: DMG1MPD
  VARIDT Drug ID: DR01116

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARC029	DMYNJHI	Alzheimer disease	8A20	Phase 3	[3]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[4]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[5]
CGS-27830	DM8TLY3	N. A.	N. A.	Terminated	[6]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[7]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[8]
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[8]
CV-4093	DM983QP	Discovery agent	N.A.	Investigative	[3]
[3H](+)-isradipine	DM7QE1J	Discovery agent	N.A.	Investigative	[9]
MEBUDIPINE	DM0P59E	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav2.1 (CACNA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flunarizine	DMZU5JP	Migraine	8A80	Approved	[11]
XEN007	DMNKV3O	Migraine	8A80	Phase 1	[11]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[12]
omega-conotoxin GVIA	DM4BQFW	Discovery agent	N.A.	Investigative	[13]
Alpha-eudesmol	DMYSCQU	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[15]
Ziconotide	DMSLJP4	Pain	MG30-MG3Z	Approved	[16]
Hesperidin	DMI5DW1	Vascular purpura	3B60	Approved	[17]
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[18]
Ralfinamide	DMUNMY0	Neuropathic pain	8E43.0	Phase 3	[19]
CNV-2197944	DMLT7JV	Pain	MG30-MG3Z	Phase 2	[20]
Ritanserin	DM0X36Y	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[21]
CNSB-004	DMHAI0M	Pain	MG30-MG3Z	Preclinical	[22]
PD-157667	DM61NFD	N. A.	N. A.	Terminated	[7]
PD-0204318	DMGKVPH	Pain	MG30-MG3Z	Terminated	[23]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RAUWOLFIA SERPENTINA ROOT	DMWTVAN	Discovery agent	N.A.	Approved	[24]
ARC029	DMYNJHI	Alzheimer disease	8A20	Phase 3	[3]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[25]
NIGULDIPINE	DMSPWMF	N. A.	N. A.	Terminated	[24]
CGS-27830	DM8TLY3	N. A.	N. A.	Terminated	[6]
R-56865	DMYTI3J	Angina pectoris	BA40	Terminated	[26]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[7]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[27]
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[27]
CORYNANTHEINE	DM18CUZ	Discovery agent	N.A.	Investigative	[24]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav2.3 (CACNA1E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)	TTZIFHC	CAC1C_HUMAN	Modulator	[2]
Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)	TT7RGTM	CAC1D_HUMAN	Modulator	[2]
Voltage-gated calcium channel alpha Cav2.1 (CACNA1A)	TTX4QDJ	CAC1A_HUMAN	Modulator	[2]
Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)	TT4FDG6	CAC1B_HUMAN	Modulator	[2]
Voltage-gated calcium channel alpha Cav2.3 (CACNA1E)	TTYRP0M	CAC1E_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
• [3] Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
• [4] Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995).
• [5] Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem. 1995 May 12;38(10):1579-81.
• [6] CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
• [7] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 530).
• [9] alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6.
• [10] Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem. 2010 May 1;18(9):3147-58.
• [11] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 532).
• [13] Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem. 2000 Nov 10;275(45):35335-44.
• [14] Alpha-eudesmol, a P/Q-type Ca(2+) channel blocker, inhibits neurogenic vasodilation and extravasation following electrical stimulation of trigeminal ganglion. Brain Res. 2000 Aug 4;873(1):94-101.
• [15] Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
• [16] Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
• [17] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [18] N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
• [19] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [20] Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
• [21] N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.
• [22] CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73.
• [23] US patent application no. 2012,0172,429, Permanently charged sodium and calcium channel blockers as anti- inflammatory agents.
• [24] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [25] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [26] Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)... J Med Chem. 1998 Oct 22;41(22):4309-16.
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529).
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 534).